Almurtide (CGP 11637) is a synthetic muramyl dipeptide (MDP) analogue with potential immunostimulating and antineoplastic activity. As a derivative of the mycobacterial cell wall component MDP, almurtide activates both monocytes and macrophages. This results in the secretion of cytokines and induces the recruitment and activation of other immune cells, which may result in indirect tumoricidal or cytostatic effects. CGP 11637 has been shown to prevent oncogenic viral infections in mice.

Norvinisterone (Nor-Progestelea) is a progestin and androgen/anabolic steroid (AAS) drug. It appeared to be quite androgenic. It was used in Europe but is no longer marketed.

Dazadrol is an antidepressant compound, developed by Schering Corp in the late 1960s. Dazadrol blocks uptake of noradrenaline and inhibits both basal and induced gastric acid secretion in the rat.

Tipetropium is atropine derivative. It is the adrenoceptor agonist. Tipetropium is bronchospasmolytic agent. It was used as anti-asthmatic drug.

Colfenamate is an antypyretic and antiinflammatory compound developed by the German company Tropon, GmbH.

Delfaprazine is an antidepressant drug, synthesized at the Spanish Centro de Investigacion, Grupo Ferrer S.A. Toxicological study in rats, rabbits, and dogs have shown that delfaprazine has less cardiotoxic side effects.

Liarozole is an imidazole-containing compound that inhibits the cytochrome P-450-dependent metabolism of all-trans-retinoic acid (RA). Liarozole, a retinoic acid (RA) metabolism-blocking agent (RAMBA) in clinical development, has been granted orphan drug designation for congenital ichthyosis by the European Commission and the U.S. Food and Drug Administration. Later, based on the mixed results from a phase II/III trial of liarozole for the treatment of ichthyosis, Barrier decided to discontinue the development of liarozole. Liarozole displays antitumor activity against androgen-dependent and independent rat prostate carcinomas.A large phase III international study was completed comparing liarozole 300 mg twice daily with cyproterone acetate (CPA) 100 mg twice daily in a total of 321 patients with metastatic prostate cancer in relapse after first-line endocrine therapy. The results indicate that liarozole might be a possible treatment option for prostate cancer (PCA) following failure of first-line endocrine therapy.

Rifametane (SPA-S-565) is a semisynthetic derivative of rifamycin (a natural antibiotic produced by Amycolatopsis rifamycinica). It was being evaluated for treatment of bacterial infections. A phase I study showed that administration of rifametane is safe with minor, reversible adverse events such as mild headache, metallic taste and slightly elevated temperature for 3 to 4 hours. Rifametane has anti-tuberculosis activity and was suggested to be a good candidate for phase II clinical trials.

Doreptide is the most active analog of PLG (Pro-Leu-Gly-NH2). It was evaluated as L-dopa potentiating agent for the treatment of Parkinson's disease.

Bemetizide was used as a thiazidediuretic. The information about the nowadays application of this drug is not available.